"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_laboratory","contact_department","contact_institute","contact_address","contact_city","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","relation","before or after first infliximab treatment:ch1","disease:ch1","response to infliximab:ch1","tissue:ch1"
"GSM364627","CO1","GSM364627","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from control individual","Homo sapiens","tissue: Colon","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364627/suppl/GSM364627.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Colon"
"GSM364628","CO2","GSM364628","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from control individual","Homo sapiens","tissue: Colon","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364628/suppl/GSM364628.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Colon"
"GSM364629","CO3","GSM364629","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from control individual","Homo sapiens","tissue: Colon","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364629/suppl/GSM364629.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Colon"
"GSM364630","CO4","GSM364630","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from control individual","Homo sapiens","tissue: Colon","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364630/suppl/GSM364630.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Colon"
"GSM364631","CO5","GSM364631","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from control individual","Homo sapiens","tissue: Colon","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364631/suppl/GSM364631.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Colon"
"GSM364632","CO6","GSM364632","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from control individual","Homo sapiens","tissue: Colon","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364632/suppl/GSM364632.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Colon"
"GSM364633","UCR1_beforeT","GSM364633","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364633/suppl/GSM364633.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","Yes","Colon"
"GSM364634","UCR2_beforeT","GSM364634","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364634/suppl/GSM364634.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","Yes","Colon"
"GSM364635","UCR3_beforeT","GSM364635","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364635/suppl/GSM364635.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","Yes","Colon"
"GSM364636","UCR4_beforeT","GSM364636","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364636/suppl/GSM364636.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","Yes","Colon"
"GSM364637","UCR5_beforeT","GSM364637","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364637/suppl/GSM364637.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","Yes","Colon"
"GSM364638","UCR6_beforeT","GSM364638","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364638/suppl/GSM364638.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","Yes","Colon"
"GSM364639","UCR7_beforeT","GSM364639","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364639/suppl/GSM364639.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","Yes","Colon"
"GSM364640","UCR8_beforeT","GSM364640","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364640/suppl/GSM364640.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","Yes","Colon"
"GSM364641","UCNR1_beforeT","GSM364641","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364641/suppl/GSM364641.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364642","UCNR2_beforeT","GSM364642","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364642/suppl/GSM364642.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364643","UCNR3_beforeT","GSM364643","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364643/suppl/GSM364643.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364644","UCNR4_beforeT","GSM364644","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364644/suppl/GSM364644.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364645","UCNR5_beforeT","GSM364645","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364645/suppl/GSM364645.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364646","UCNR6_beforeT","GSM364646","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364646/suppl/GSM364646.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364647","UCNR7_beforeT","GSM364647","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364647/suppl/GSM364647.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364648","UCNR8_beforeT","GSM364648","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364648/suppl/GSM364648.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364649","UCNR9_beforeT","GSM364649","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364649/suppl/GSM364649.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364650","UCNR10_beforeT","GSM364650","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364650/suppl/GSM364650.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364651","UCNR11_beforeT","GSM364651","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364651/suppl/GSM364651.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364652","UCNR12_beforeT","GSM364652","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364652/suppl/GSM364652.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364653","UCNR13_beforeT","GSM364653","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364653/suppl/GSM364653.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364654","UCNR14_beforeT","GSM364654","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364654/suppl/GSM364654.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364655","UCNR15_beforeT","GSM364655","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364655/suppl/GSM364655.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM364656","UCNR16_beforeT","GSM364656","Public on Nov 03 2009","Jan 26 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364656/suppl/GSM364656.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","UC","No","Colon"
"GSM422963","UCR1_afterT","GSM422963","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422963/suppl/GSM422963.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","Yes","Colon"
"GSM422965","UCR2_afterT","GSM422965","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422965/suppl/GSM422965.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","Yes","Colon"
"GSM422967","UCR3_afterT","GSM422967","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422967/suppl/GSM422967.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","Yes","Colon"
"GSM422969","UCR4_afterT","GSM422969","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422969/suppl/GSM422969.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","Yes","Colon"
"GSM422971","UCR5_afterT","GSM422971","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422971/suppl/GSM422971.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","Yes","Colon"
"GSM422973","UCR6_afterT","GSM422973","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422973/suppl/GSM422973.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","Yes","Colon"
"GSM422975","UCR7_afterT","GSM422975","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422975/suppl/GSM422975.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","Yes","Colon"
"GSM422977","UCR8_afterT","GSM422977","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422977/suppl/GSM422977.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","Yes","Colon"
"GSM422979","UCNR1_afterT","GSM422979","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422979/suppl/GSM422979.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422981","UCNR2_afterT","GSM422981","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422981/suppl/GSM422981.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422983","UCNR3_afterT","GSM422983","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422983/suppl/GSM422983.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422985","UCNR4_afterT","GSM422985","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422985/suppl/GSM422985.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422987","UCNR5_afterT","GSM422987","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422987/suppl/GSM422987.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422989","UCNR6_afterT","GSM422989","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422989/suppl/GSM422989.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422991","UCNR7_afterT","GSM422991","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422991/suppl/GSM422991.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422993","UCNR8_afterT","GSM422993","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422993/suppl/GSM422993.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422995","UCNR9_afterT","GSM422995","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422995/suppl/GSM422995.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422997","UCNR10_afterT","GSM422997","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422997/suppl/GSM422997.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM422999","UCNR11_afterT","GSM422999","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422999/suppl/GSM422999.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM423001","UCNR12_afterT","GSM423001","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423001/suppl/GSM423001.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM423003","UCNR13_afterT","GSM423003","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423003/suppl/GSM423003.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM423005","UCNR14_afterT","GSM423005","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423005/suppl/GSM423005.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM423007","UCNR15_afterT","GSM423007","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423007/suppl/GSM423007.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM423009","UCNR16_afterT","GSM423009","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from UC non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: UC","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from UC non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423009/suppl/GSM423009.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","UC","No","Colon"
"GSM423010","CDcR1_beforeT","GSM423010","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423010/suppl/GSM423010.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423011","CDcR1_afterT","GSM423011","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423011/suppl/GSM423011.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423012","CDcR2_beforeT","GSM423012","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423012/suppl/GSM423012.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423013","CDcR3_beforeT","GSM423013","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423013/suppl/GSM423013.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423014","CDcR3_afterT","GSM423014","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423014/suppl/GSM423014.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423015","CDcR4_beforeT","GSM423015","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423015/suppl/GSM423015.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423016","CDcR4_afterT","GSM423016","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423016/suppl/GSM423016.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423017","CDcR5_beforeT","GSM423017","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423017/suppl/GSM423017.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423018","CDcR5_afterT","GSM423018","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423018/suppl/GSM423018.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423019","CDcR6_beforeT","GSM423019","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423019/suppl/GSM423019.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423020","CDcR6_afterT","GSM423020","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423020/suppl/GSM423020.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423021","CDcR7_beforeT","GSM423021","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423021/suppl/GSM423021.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423022","CDcR7_afterT","GSM423022","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423022/suppl/GSM423022.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423023","CDcR8_beforeT","GSM423023","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423023/suppl/GSM423023.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423024","CDcR8_afterT","GSM423024","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423024/suppl/GSM423024.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423025","CDcR9_beforeT","GSM423025","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423025/suppl/GSM423025.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423026","CDcR9_afterT","GSM423026","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423026/suppl/GSM423026.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423027","CDcR10_beforeT","GSM423027","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423027/suppl/GSM423027.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423028","CDcR10_afterT","GSM423028","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423028/suppl/GSM423028.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423029","CDcR11_beforeT","GSM423029","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423029/suppl/GSM423029.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423030","CDcR11_afterT","GSM423030","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423030/suppl/GSM423030.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423031","CDcR12_beforeT","GSM423031","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423031/suppl/GSM423031.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Colon"
"GSM423032","CDcR12_afterT","GSM423032","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423032/suppl/GSM423032.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Colon"
"GSM423033","CDcNR1_beforeT","GSM423033","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423033/suppl/GSM423033.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Colon"
"GSM423034","CDcNR1_afterT","GSM423034","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423034/suppl/GSM423034.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Colon"
"GSM423035","CDcNR2_beforeT","GSM423035","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423035/suppl/GSM423035.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Colon"
"GSM423036","CDcNR2_afterT","GSM423036","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423036/suppl/GSM423036.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Colon"
"GSM423037","CDcNR3_beforeT","GSM423037","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423037/suppl/GSM423037.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Colon"
"GSM423038","CDcNR3_afterT","GSM423038","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423038/suppl/GSM423038.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Colon"
"GSM423039","CDcNR4_beforeT","GSM423039","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423039/suppl/GSM423039.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Colon"
"GSM423040","CDcNR4_afterT","GSM423040","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423040/suppl/GSM423040.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Colon"
"GSM423041","CDcNR5_beforeT","GSM423041","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423041/suppl/GSM423041.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Colon"
"GSM423042","CDcNR5_afterT","GSM423042","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423042/suppl/GSM423042.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Colon"
"GSM423043","CDcNR6_beforeT","GSM423043","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423043/suppl/GSM423043.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Colon"
"GSM423044","CDcNR6_afterT","GSM423044","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423044/suppl/GSM423044.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Colon"
"GSM423045","CDcNR7_beforeT","GSM423045","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder before first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423045/suppl/GSM423045.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Colon"
"GSM423046","CDcNR7_afterT","GSM423046","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Colonic mucosal biopsy from CDc non-responder after first infliximab treatment","Homo sapiens","tissue: Colon","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423046/suppl/GSM423046.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Colon"
"GSM423047","IL1","GSM423047","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from control individual","Homo sapiens","tissue: Ileum","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423047/suppl/GSM423047.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Ileum"
"GSM423048","IL2","GSM423048","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from control individual","Homo sapiens","tissue: Ileum","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423048/suppl/GSM423048.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Ileum"
"GSM423049","IL3","GSM423049","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from control individual","Homo sapiens","tissue: Ileum","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423049/suppl/GSM423049.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Ileum"
"GSM423050","IL4","GSM423050","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from control individual","Homo sapiens","tissue: Ileum","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423050/suppl/GSM423050.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Ileum"
"GSM423051","IL5","GSM423051","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from control individual","Homo sapiens","tissue: Ileum","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423051/suppl/GSM423051.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Ileum"
"GSM423052","IL6","GSM423052","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from control individual","Homo sapiens","tissue: Ileum","disease: Control","response to infliximab: Not applicable","before or after first infliximab treatment: Not applicable","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from control individual","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423052/suppl/GSM423052.CEL.gz","54675","Reanalyzed by: GSE119087","Not applicable","Control","Not applicable","Ileum"
"GSM423053","CDiR1_beforeT","GSM423053","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423053/suppl/GSM423053.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Ileum"
"GSM423054","CDiR1_afterT","GSM423054","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423054/suppl/GSM423054.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Ileum"
"GSM423055","CDiR2_beforeT","GSM423055","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423055/suppl/GSM423055.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Ileum"
"GSM423056","CDiR2_afterT","GSM423056","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423056/suppl/GSM423056.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Ileum"
"GSM423057","CDiR3_beforeT","GSM423057","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423057/suppl/GSM423057.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Ileum"
"GSM423058","CDiR3_afterT","GSM423058","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423058/suppl/GSM423058.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Ileum"
"GSM423059","CDiR4_beforeT","GSM423059","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423059/suppl/GSM423059.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Ileum"
"GSM423060","CDiR4_afterT","GSM423060","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423060/suppl/GSM423060.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Ileum"
"GSM423061","CDiR5_beforeT","GSM423061","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423061/suppl/GSM423061.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Ileum"
"GSM423062","CDiR5_afterT","GSM423062","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423062/suppl/GSM423062.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Ileum"
"GSM423063","CDiR6_beforeT","GSM423063","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423063/suppl/GSM423063.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Ileum"
"GSM423064","CDiR6_afterT","GSM423064","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423064/suppl/GSM423064.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Ileum"
"GSM423065","CDiR7_beforeT","GSM423065","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423065/suppl/GSM423065.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Ileum"
"GSM423066","CDiR7_afterT","GSM423066","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423066/suppl/GSM423066.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Ileum"
"GSM423067","CDiR8_beforeT","GSM423067","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423067/suppl/GSM423067.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","Yes","Ileum"
"GSM423068","CDiR8_afterT","GSM423068","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: Yes","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423068/suppl/GSM423068.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","Yes","Ileum"
"GSM423069","CDiNR1_beforeT","GSM423069","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423069/suppl/GSM423069.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423070","CDiNR1_afterT","GSM423070","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423070/suppl/GSM423070.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423071","CDiNR2_beforeT","GSM423071","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423071/suppl/GSM423071.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423072","CDiNR2_afterT","GSM423072","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423072/suppl/GSM423072.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423073","CDiNR3_beforeT","GSM423073","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423073/suppl/GSM423073.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423074","CDiNR3_afterT","GSM423074","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423074/suppl/GSM423074.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423075","CDiNR4_beforeT","GSM423075","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423075/suppl/GSM423075.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423076","CDiNR4_afterT","GSM423076","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423076/suppl/GSM423076.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423077","CDiNR5_beforeT","GSM423077","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423077/suppl/GSM423077.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423078","CDiNR5_afterT","GSM423078","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423078/suppl/GSM423078.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423079","CDiNR6_beforeT","GSM423079","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423079/suppl/GSM423079.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423080","CDiNR6_afterT","GSM423080","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423080/suppl/GSM423080.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423081","CDiNR7_beforeT","GSM423081","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423081/suppl/GSM423081.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423082","CDiNR7_afterT","GSM423082","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423082/suppl/GSM423082.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423083","CDiNR8_beforeT","GSM423083","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423083/suppl/GSM423083.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423084","CDiNR8_afterT","GSM423084","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423084/suppl/GSM423084.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423085","CDiNR9_beforeT","GSM423085","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423085/suppl/GSM423085.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423086","CDiNR9_afterT","GSM423086","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423086/suppl/GSM423086.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
"GSM423087","CDiNR10_beforeT","GSM423087","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder before first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: Before first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423087/suppl/GSM423087.CEL.gz","54675","Reanalyzed by: GSE119087","Before first infliximab treatment","CD","No","Ileum"
"GSM423088","CDiNR10_afterT","GSM423088","Public on Nov 03 2009","Jun 29 2009","Aug 28 2018","RNA","1","Ileal mucosal biopsy from CDi non-responder after first infliximab treatment","Homo sapiens","tissue: Ileum","disease: CD","response to infliximab: No","before or after first infliximab treatment: After first infliximab treatment","total RNA","Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturer’s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.","biotin","Total RNA (2 µg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.","9606","Fragmented cRNA (15 µg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).","The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.","Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment","The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.","GPL570","Ingrid,,Arijs","ingrid.arijs@med.kuleuven.be","TARGID - IBD Leuven","Clinical and Experimental Medicine","KULeuven","Herestraat 49","Leuven","3000","Belgium","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423088/suppl/GSM423088.CEL.gz","54675","Reanalyzed by: GSE119087","After first infliximab treatment","CD","No","Ileum"
